newsfilter
← Latest News
GlobeNewswire·

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the Clinical Journal